RxDoctor Payments Data

Whitney Irvine, APRN

Family · Suffolk, VANPI 1841893351

Payments from drug & device makers

$722in general payments, 2019–2025

Across 40 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$245
  • AbbVie$181
  • AstraZeneca$57
  • Pfizer$56
  • Exeltis, USA Inc.$52
  • Lilly USA, LLC$49
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$722 in reported general payments places this provider in the 65th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$98,233
Medicare patients
299
Services billed
1,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$34,261
TrulicityDulaglutide47$24,247
FarxigaDapagliflozin Propanediol54$12,085
MyrbetriqMirabegron41$9,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$9,252
XareltoRivaroxaban27$8,291
Potassium Chloride57$4,774
Gabapentin340$4,673
Atorvastatin Calcium247$4,276
Midodrine Hcl20$3,843
BelsomraSuvorexant23$3,833
JanuviaSitagliptin Phosphate11$3,188
Divalproex Sodium16$2,740
Lacosamide28$2,522
Insulin Lispro Kwikpen U-100Insulin Lispro58$2,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$34,26199 claims
Lilly USA, LLCTrulicity$49$24,24747 claims
AstraZenecaFarxiga$57$12,08554 claims
MerckBelsomra, Januvia$15$7,02034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,332 family providers in Virginia.

Other family in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →